As is well known for other tumor markers such as CA 19-9, one can also detect elevated levels in benign diseases of the pancreas. In conclusion, pancreatic cancer Tumor M2-PK and CA 19-9 cannot be ...

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer. This means it grows and ...

Unfortunately, many solid tumors metastasize to other organs, which limits treatment efficacy. One specific cancer type that is extremely aggressive and often metastasizes includes pancreatic cancer.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

BASKING RIDGE, N.J. - Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage biotech company with a market capitalization of $23 million, in collaboration with WARPNINE Incorporated, has announced ...

TLSs serve as the immune system’s on-site responders, forming in chronically inflamed tissues, including tumors, to bolster ...

The latest grant is intended to support the company’s Phase 1 PANACEA study evaluating the safety and tolerability of MT-601 in patients with metastatic pancreatic cancer. Marker Therapeutics ...

(RTTNews) - Immuno-oncology company Marker Therapeutics ... investigation of MT-601 in patients with metastatic pancreatic cancer. The CPRIT grant is intended to support the Company's Phase ...

A revolutionary blood test, TriOx, developed by researchers at the University of Oxford, is demonstrating significant ...